MorphoSys and MD Anderson Cancer Center Join Forces for the Development of Novel Oncology Therapeutics - Seite 3
About ORBIT
ORBIT (Oncology Research for Biologics and Immunotherapy Translation) platform is a novel MD Anderson
platform with the mission of making MD Anderson a recognized leader in the discovery and development of novel monoclonal antibodies. The ORBIT team focuses on combining scientific excellence with
industry standards and is committed to accelerate and execute the translation of novel discoveries into clinically relevant anti-cancer mAbs. ORBIT's scientific directors are Jeffrey Molldrem,
M.D., professor of Stem Cell Transplantation and Cellular Therapy and Michael Curran, Ph.D., assistant professor of Immunology.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Lesen Sie auch
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / Munich Germany
WKN: 663200;ISIN: DE0006632003;Index:TECH All Share,CDAX,Prime All Share,TecDAX,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;